BR112022010687A2 - Cepas de reovírus aviário atenuado 94826 c140 e 96139 c140 - Google Patents

Cepas de reovírus aviário atenuado 94826 c140 e 96139 c140

Info

Publication number
BR112022010687A2
BR112022010687A2 BR112022010687A BR112022010687A BR112022010687A2 BR 112022010687 A2 BR112022010687 A2 BR 112022010687A2 BR 112022010687 A BR112022010687 A BR 112022010687A BR 112022010687 A BR112022010687 A BR 112022010687A BR 112022010687 A2 BR112022010687 A2 BR 112022010687A2
Authority
BR
Brazil
Prior art keywords
avian reovirus
attenuated
avian
reovirus
tenosynovitis
Prior art date
Application number
BR112022010687A
Other languages
English (en)
Inventor
S Sellers Holly
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of BR112022010687A2 publication Critical patent/BR112022010687A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12061—Methods of inactivation or attenuation
    • C12N2720/12064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CEPAS DE REOVÍRUS AVIÁRIO ATENUADO 94826 C140 E 96139 C140. Isolados atenuados de reovírus aviários associados a artrite viral/tenossinovite em aves domésticas são apresentados, incluindo a cepa de reovírus aviário 94826 C140 depositada na ATCC sob a designação de patente PTA-126077 e a progênie ou os derivados da mesma e a cepa de reovírus aviário 96139 C140 depositada na ATCC sob a designação de patente PTA-126078 e a progênie ou os derivados da mesma. Composições e métodos para administrar os isolados ou as composições como vacinas para o controle da artrite viral/tenossinovite induzida por reovírus em aves da ordem Galliformes também são apresentados.
BR112022010687A 2019-12-02 2020-12-01 Cepas de reovírus aviário atenuado 94826 c140 e 96139 c140 BR112022010687A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942426P 2019-12-02 2019-12-02
PCT/US2020/062651 WO2021113206A1 (en) 2019-12-02 2020-12-01 Attenuated avian reovirus strains 94826 c140 and 96139 c140

Publications (1)

Publication Number Publication Date
BR112022010687A2 true BR112022010687A2 (pt) 2022-08-23

Family

ID=76221714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010687A BR112022010687A2 (pt) 2019-12-02 2020-12-01 Cepas de reovírus aviário atenuado 94826 c140 e 96139 c140

Country Status (7)

Country Link
US (1) US20230000972A1 (pt)
EP (1) EP4069289A4 (pt)
JP (1) JP2023504225A (pt)
CN (1) CN114828883A (pt)
BR (1) BR112022010687A2 (pt)
MX (1) MX2022006546A (pt)
WO (1) WO2021113206A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478937B (zh) * 2023-06-12 2023-08-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 基因iii型禽呼肠孤病毒变异株及其在制备疫苗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232808A (zh) 2014-01-29 2016-12-14 乔治亚大学研究基金公司 禽类呼肠孤病毒疫苗
CA3026241A1 (en) * 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections

Also Published As

Publication number Publication date
MX2022006546A (es) 2022-07-01
JP2023504225A (ja) 2023-02-01
EP4069289A1 (en) 2022-10-12
WO2021113206A1 (en) 2021-06-10
US20230000972A1 (en) 2023-01-05
EP4069289A4 (en) 2023-11-29
CN114828883A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
BARBERIS et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines
BR112019023758A2 (pt) vírus da doença newcastle e seus usos
BR112018070859A2 (pt) degradantes da proteína de bet
BR112012033227A2 (pt) análogos do glucagon
BR112018070962A2 (pt) espécies bacterianas inovadoras
CO2021017317A2 (es) Células seguras e invisibles para el sistema inmunitario
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
BR112022010687A2 (pt) Cepas de reovírus aviário atenuado 94826 c140 e 96139 c140
BR112021012616A2 (pt) Cepa produtora de ergotioneína e método para triagem da mesma
BR112014011443A2 (pt) bactérias do ácido láctico e seu uso como suplementos alimentares para aves domésticas
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
CN107208071B (zh) 用于流感病毒的减弱活疫苗
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
BR112023020077A2 (pt) Compostos de oxoisoindolina substituída por piridinila
BR112017013999A2 (pt) ?composição derivada de uma bifidobactéria?
BR112021024810A2 (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas
BR112016017242A2 (pt) Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
BR112014030623A2 (pt) composição, combinação e respectivos usos
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
AR085800A1 (es) Vacuna de rinitis equina
ECSP22064620A (es) COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2
BR112021024363A2 (pt) Purificação de saponina
BR112023020732A2 (pt) Vetor lentiviral para o tratamento da hepatite b, método e preparação de partículas lentivirais para o tratamento da mesma e composição farmacêutica para o tratamento e/ou prevenção da infecção pelo vírus da hepatite b
BR112023005001A2 (pt) Isolado atenuado do vírus da estirpe dmv1639 de bronquite infecciosa